PDL1 immunohistochemistry in canine neoplasms: Validation of commercial antibodies, standardization of evaluation, and scoring systems

Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems

(2022) Stefano Marletta et al.   Journal of Personalized Medicine

Comparative Evaluation of Tumor-Infiltrating Lymphocytes in Companion Animals: Immuno-Oncology as a Relevant Translational Model for Cancer Therapy

(2022) Christopher J. Pinard et al.   Cancers

Prognostic value of tumor-infiltrating immune cells and immune checkpoints in elderly head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiotherapy

(2022) Alexander Rühle et al.   Radiation Oncology

Development of Monoclonal Antibodies Targeting Canine PD-L1 and PD-1 and Their Clinical Relevance in Canine Apocrine Gland Anal Sac Adenocarcinoma

(2022) Lucia Minoli et al.   Cancers

High expression of ACE2 and TMPRSS2 and clinical characteristics of COVID-19 in colorectal cancer patients

(2021) Chao Liu et al.   npj Precision Oncology

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

(2021) Deborah Blythe Doroshow et al.   Nature Reviews Clinical Oncology

Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs

(2021) Stanislav Pantelyushin et al.   Cancers

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

(2021) Mengke Niu et al.   Experimental Hematology & Oncology

Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies

(2021) Bethany Bareham et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade

(2021) Sneha Berry et al.   SCIENCE

PD−L1 immunostaining: what pathologists need to know

(2021) Mohammed Akhtar et al.   Diagnostic Pathology

Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines

(2021) Christopher J. Pinard et al.   VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

(2020) Nasser H. Hanna et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function

(2020) Jin Wook Choi et al.   PLoS One

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors

(2020) Qingyang Lei et al.   Frontiers in Cell and Developmental Biology

Nuclear localization of PD-L1: artifact or reality?

(2019) Hara Polioudaki et al.   CELLULAR ONCOLOGY

Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases

(2019) Dennis P. O’Malley et al.   MODERN PATHOLOGY

Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers

(2019) Konrad Pawelczyk et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

(2019) Caroline Robert et al.   LANCET ONCOLOGY

Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms

(2018) Christina Koppel et al.   MODERN PATHOLOGY

PD-L1

(2017) Anthousa Kythreotou et al.   JOURNAL OF CLINICAL PATHOLOGY

Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies

(2016) M. F. Sanmamed et al.   ANNALS OF ONCOLOGY

PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases

(2016) Emanuela Veras et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis

(2016) Nathaniel A. Slater et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

PD-L1 expression in human cancers and its association with clinical outcomes

(2016) Jinming Yu et al.   OncoTargets and Therapy

PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations

(2016) Andreas H. Scheel et al.   OncoImmunology

Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma

(2016) Naoya Maekawa et al.   PLoS One

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology